Equities Analysts Issue Forecasts for CNTA FY2025 Earnings

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Leerink Partnrs lowered their FY2025 EPS estimates for shares of Centessa Pharmaceuticals in a research note issued on Tuesday, August 12th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($1.37) per share for the year, down from their prior estimate of ($1.34). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.67) EPS, FY2028 earnings at ($1.86) EPS and FY2029 earnings at $0.77 EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price target for the company. Finally, Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a “buy” rating and a $35.00 price target for the company. One analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $28.10.

Centessa Pharmaceuticals Stock Up 2.3%

CNTA stock opened at $18.05 on Friday. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -10.08 and a beta of 1.48. The company has a current ratio of 10.11, a quick ratio of 14.37 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $19.09. The firm has a 50-day moving average of $14.76 and a two-hundred day moving average of $14.49.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03).

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at $47,000. Barclays PLC lifted its position in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at $147,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Activity at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $17.23, for a total value of $103,380.00. Following the completion of the sale, the general counsel owned 105,386 shares in the company, valued at approximately $1,815,800.78. This trade represents a 5.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mario Alberto Accardi sold 8,322 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total transaction of $126,744.06. Following the completion of the sale, the insider owned 208,163 shares of the company’s stock, valued at $3,170,322.49. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 236,322 shares of company stock worth $3,300,064 over the last quarter. Company insiders own 7.09% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.